H. Lundbeck A/S

Stories

Lundbeck trial shows VYEPTI helps migraine patients who failed other CGRP drugs

Develops and markets VYEPTI (eptinezumab); sponsored the THRIVE trial

Migraine patients who try one CGRP-blocking drug and get no relief now have evidence that switching to a different one can work. In Lundbeck's Phase IV THRIVE trial, 60% of participants still in the study after 24 weeks on VYEPTI (eptinezumab) reported being 'much improved' or 'very much improved.'

Updated Oct 20

Alkermes enters sleep medicine market through Avadel acquisition

Money Moves

As of May 2026: Lost bidding war for Avadel

Alkermes, a neuroscience-focused pharmaceutical company, completed its $2.37 billion acquisition of Avadel Pharmaceuticals on February 12, 2026, gaining immediate entry into the sleep medicine market. The deal adds LUMRYZ, the only once-nightly narcolepsy treatment, to Alkermes' portfolio alongside an emerging pipeline of orexin-based therapies.

Updated May 27